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ABSTRACT
Objectives: Cancer-associated thrombosis (CAT)
complex condition, which may present to any
healthcare professional and at any point during the
cancer journey. As such, patients may be managed by
a number of specialties, resulting in inconsistent
practice and suboptimal care. We describe the
development of a dedicated CAT service and its
evaluation.
Setting: Specialist cancer centre, district general
hospital and primary care.
Participants: Patients with CAT and their referring
clinicians.
Intervention: A cross specialty team developed a
dedicated CAT service , including clear referral
pathways, consistent access to medicines, patient’s
information and a specialist clinic.
Primary and secondary outcome measures:
The service was evaluated using a mixed-methods
evaluation , including audits of clinical practice, clinical
outcomes, staff surveys and qualitative interviewing of
patients and healthcare professionals.
Results: Data from 457 consecutive referrals over an
18-month period were evaluated. The CAT service has
led to an 88% increase in safe and consistent
community prescribing of low-molecular-weight
heparin, with improved access to specialist advice and
information. Patients reported improved understanding
of their condition, enabling better self-management as
well as better access to support and information.
Referring clinicians reported better care standards for
their patients with improved access to expertise and
appropriate management.
Conclusions: A dedicated CAT service improves
overall standards of care and is viewed positively by
patients and clinicians alike. Further health economic
evaluation would enhance the case for establishing this
as the standard model of care.
INTRODUCTION
The association between malignancy and
thrombosis is well established; cancer
accounts for 18% of all cases of venous
thromboembolism (VTE) and will occur in
20% of patients with cancer.1 The manage-
ment of cancer-associated thrombosis (CAT)
is associated with particular clinical chal-
lenges.2 Anticoagulation with warfarin is asso-
ciated with an increased risk of haemorrhage
and recurrent thrombosis compared to
patients without cancer.3 4 Consequently,
low-molecular-weight heparin (LMWH) has
demonstrated greater efﬁcacy than warfarin
in the treatment of CAT and remains the
anticoagulant of choice in clinical guide-
lines.5–8 More recently, the direct-acting oral
anticoagulants (DOACs) have demonstrated
non-inferiority to warfarin in the treatment
of VTE in the general population.9–12 While
they are yet to be evaluated against LMWH
for the treatment of CAT, their use in the
cancer setting is increasing.13
Despite a strong evidence base for best
practice, adherence to clinical guidelines is
variable and decision-making is inconsistent
across the specialties involved in the manage-
ment of CAT.14 15 This problem is com-
pounded by a lack of clinical ownership for
CAT between oncology, haematology and
primary care, thereby leading problems with
Strengths and limitations of this study
▪ This is the first description of a dedicated
cancer-associated thrombosis service.
▪ It provides quantitative and qualitative evidence
of improved quality of care and reduction in
avoidable harm.
▪ It provides real-world data on the scope of
patients with cancer-associated thrombosis pre-
senting to a regional cancer centre.
▪ It offers a readily reproducible service model that
can be adopted across the health system.
▪ While the benefits of the service model are clear,
it has not been subjected to formal health eco-
nomic evaluation.
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accessing medication, follow-up and ongoing decision-
making.16 17 Furthermore, the sequelae of CAT are not
limited to the physical; recent research has suggested
that it confers a signiﬁcant symptomatic and psycho-
logical burden on patients and is considered by some to
be more distressing than cancer itself.17 18 As such, a
holistic approach to CAT is essential, particularly as
these patients will also have needs within the context of
their cancer journey.19 A recent case series of 221 US
patients suggests that a centralised approach to the care
of CAT reduces treatment variation and appears to
reduce VTE-related hospitalisations.20 This leads to cost
savings through reduction in recurrent VTE, bleeding
and hospital admissions.
We describe the development and evaluation of a
dedicated CAT service within a UK regional cancer
centre.
CLINICAL CONTEXT AND NEED FOR NEW SERVICE
The dedicated CAT service was developed in response to
an audit of the management of VTE in oncology
patients attending a regional cancer centre, serving a
population of 1.42 million with 7000 new cancer diagno-
ses per annum. Several areas of unmet need and oppor-
tunities for improvement were identiﬁed, including
variation in clinical management, problems in accessing
LMWH in the community, increased need for support
and information and the absence of consistent access to
specialist advice. These are summarised in box 1.
A multiprofessional team with representation from
oncology, haematology, primary care and palliative care
devised a new model of working with the intention of
improving the quality of patient care and experience
while reducing variation, wastage and harm.
DEVELOPMENT OF NEW SERVICE
The patient journey and key components of the CAT
service are summarised in ﬁgure 1. The new service was
established through the implementation of four core
components, described below. The service was funded
through existing National Health Service resources, with
no input ﬁnancially or intellectually from any members
of the pharmaceutical industry.
Shared care agreement for community prescribing
of LMWH
A working group was established between clinical stake-
holders within primary and secondary care to establish a
shared care protocol, which would support the prescrib-
ing within primary care of LMWH for the treatment of
VTE in solid tumours as per license. Once agreed, the
relevant local prescribing and commissioning groups
ratiﬁed this, after which details of the agreement were
disseminated to all healthcare practitioners likely to be
involved. Part of the prescribing agreement required
primary care to sign and return the document
indicating agreement to participate, thereby ensuring
that the uptake of the shared care agreement was
auditable.
Patient information leaflets
Two patient leaﬂets were designed to provide
▸ Information about referral to the CAT clinic;
▸ Advice on self-injecting LMWH.
The documents were developed in consultation with
two patients currently being treated for CAT who offered
advice regarding their preferred information needs at
the time of diagnosis. Documents were then taken
through local approval processes , including the patient
partner group and plain English campaign (http://www.
plainenglish.co.uk/).
Patient referral pathway
The patient pathway was piloted within one cancer
centre and subsequently expanded to district general
hospitals that fed into the tertiary centre. This was per-
formed following a broad education programme to
make clinicians aware of the new service. Referrals were
made at the point of diagnosis of CAT to a dedicated
CAT secretary and reviewed by the CAT clinician within
Box 1 Challenges to the provision of high-quality cancer-
associated thrombosis (CAT) management
I. Inconsistent management of CAT and adherence to guidelines
Variation in practice was observed across clinical teams with
respect to the following key areas of anticoagulation:
▸ Measurement of baseline blood tests prior to starting
low-molecular-weight heparin (LMWH);
▸ Review of full blood count at day 5 post-LMWH initiation;
▸ Dose reduction of dalteparin after 1 month of anticoagulation;
▸ Decision on whether to continue or stop anticoagulation at
6 months for patients with ongoing active cancer.
II. Variable access to LMWH
LMWH would usually be initiated within the hospital setting
with the expectation that ongoing anticoagulation would be
managed by the primary care/family physician. Inconsistent
willingness to take on this prescribing leads to increased dis-
tress for patients and unclear pathways of access to repeat
prescriptions.
III. Need for information and support
Distress associated with suboptimal communication and lack
of information was identified pertaining to:
▸ Understanding the meaning and prognosis of CAT;
▸ LMWH injection techniques;
▸ Plans for follow-up.
IV. Lack of consistent specialist expertise
Twenty per cent of patients required management beyond
standard weight-adjusted LMWH therapy. There was no con-
sistent pathway or access to expert advice on managing:
▸ Recurrent venous thromboembolism;
▸ Bleeding;
▸ Thrombocytopenia;
▸ Interventions (eg, biopsies) and interruption of anticoagulation;
▸ Inferior vena cava filters.
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24 hours. The clinical team, responsible for the patient,
did this at the time the CAT was diagnosed. A written
referral would be faxed or emailed to the CAT secretary
who would ensure that it was reviewed by one of the
CAT clinicians (SN or NP) within 24 hours. They would
decide how quickly the patient should. For the majority
of patients with uncomplicated symptomatic or inciden-
tal VTE, an appointment would be sent to review within
4 weeks of diagnosis. At this time, the referring clinician
would be responsible for:
▸ Baseline blood tests: full blood count, renal and liver
function and coagulation screen.
▸ Providing 4 weeks of LMWH (patient information
leaﬂets will be dispensed by pharmacy).
▸ Ensuring that LMWH is administered by a trained
patient/carer or domiciliary visit by the district nurse.
▸ Check platelet count 5 days after LMWH initiated to
check for heparin-induced thrombocytopenia.
On occasion, the clinician reviewing the referral may
feel that the patient requires immediate review, for
example, large volume clot burden, renal impairment
and bleeding risk. For these patients, advice would be
given to the referring clinician on receipt and a review
arranged in the next available clinic.
Dedicated outpatient clinic
Details of issues covered in the clinic are summarised in
ﬁgure 1. The ﬁrst clinic appointment would occur
4 weeks post-CAT diagnosis, thereby ensuring that a
review occurs at the time point for LMWH dose reduc-
tion (for centres where dalteparin was used). Practical
issues that are addressed during this ﬁrst appointment
include reviewing injection technique, evaluation for
any episodes suggestive of bleeding or recurrent CAT,
and ensuring that the shared care agreement is com-
pleted. The clinician will also ensure that there is an
up-to-date record of patient weight and routine bloods
(full blood count and electrolytes).
At this meeting, patients would have an opportunity to
discuss any aspect of their CAT management. From our
experience, the following issues are of importance to
them:
▸ Why they got the CAT.
▸ Why they are on an injectable anticoagulant and not
an oral agent.
▸ How long they should be anticoagulated.
▸ How one evaluates whether the clot has gone.
▸ The likelihood of clot recurrence.
▸ Would the treatment for CAT affect their cancer
treatment?
For the majority of patients with uncomplicated CAT,
the management would require another appointment
2–3 months later to evaluate progress followed by an
appointment after 6 months’ anticoagulation. This
would be the ﬁnal appointment for patients who no
longer have cancer, and it is essential that patients be
alerted to the following:
▸ Patients have an ongoing risk of VTE in the future.
▸ The need for risk assessment and thromboprophy-
laxis at future hospital admissions.
▸ The signs and symptoms of VTE that would warrant
medical evaluation.
In those with ongoing active cancer and/or receiving
chemotherapy, consideration will be made on a case-
by-case basis regarding continued anticoagulation, choice
of anticoagulant and the agreed prescriber.21 Follow-up
will be determined according to the complexity of their
case, clinical condition and access to anticoagulants.
EVALUATION OF SERVICE
Methods
The service was evaluated using the research question
‘What is the impact of a dedicated CAT service on the
quality of patient care’ using the following ‘PICO’ (popu-
lation, intervention, comparator, outcome) framework:
▸ Population: patients with cancer diagnosed with acute
VTE.
▸ Intervention: referral to regional CAT service.
Figure 1 Referral and management pathway for
cancer-associated thrombosis. CAT, cancer-associated
thrombosis; FBC, full blood count; U+E, urea and elctrolytes;
LFT, liver function tests. LMWH, low-molecular-weight
heparin, VTE, venous thromboembolism
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▸ Comparator: patient data from initial audit, which
established need to establish CAT service.
▸ Outcome: multiple outcomes, including
– Audit of the uptake of the shared care agreement;
– Patient evaluations through qualitative interviewing;
– Oncologist evaluations through qualitative
interviews.
The service was evaluated through a mixed-methods
approach, which comprised a prospective audit of clin-
ical data, review of the uptake of the shared care agree-
ment, and qualitative interviewing of referred patients
and their referring clinicians following a wider clinician
survey, as detailed below.
Audit data were prospectively collected to capture
basic patient demographics, cancer type and details of
the type of VTE diagnosed. Patients were evaluated to
see whether they qualiﬁed to be managed according to
the shared care agreement, which was then sent to their
primary care team. Agreement to participate in the
shared care agreement and hence prescribe LMWH in
the community was indicated by signing and returning
the document. The proportion of returned documents
was compared with the proportion of patients receiving
community LMWH at the time of the initial audit.
A full description of the qualitative methodology has
been reported previously.19 Qualitative interviews are
composed of two components: the ﬁrst being interviews
with CAT patients under the care of the CAT service and
the second with oncologists who had referred patients.
The interviewer (HP), who was from a nursing back-
ground, had no prior relationship with participants or
declared clinical interest in CAT management. Data
from patients were elicited on the following:
▸ Their experience of being diagnosed with CAT
▸ Their experience of the CAT service
▸ How their care could be improved
Data from referring oncologists were elicited on
▸ Their experience of managing CAT
▸ Their views of the CAT service
▸ How their care could be improved.
To facilitate this, questions were open-ended with the
use of prompts to probe further into issues, which arose
as signiﬁcant or meaningful to the participant.
Interviews were digitally recorded and transcribed verba-
tim. Field notes were also taken. Interviews took
∼40 minutes each. No repeat interviews were necessary;
neither did any aspects of transcripts require additional
checking with participants.
Analysis
Transcripts were typed into a Word document and
uploaded to NVivo V.10 computer software for data man-
agement.22 Data analysis was undertaken using a frame-
work analysis (FA). This was considered the most
appropriate analytic method to enable a deductive
approach towards creating an analytic framework based
on the interview schedule, while also allowing room for
inductive observations. Analysis was undertaken using
the ﬁve interconnected stages inherent in FA:23
1. Familiarisation with data
2. Identifying a thematic framework
3. Indexing the data
4. Charting
5. Mapping and interpretation.
RESULTS
Over an 18-month period, 457 patients were seen
through the CAT service of which 230 (50.4%) were
male and 227 (49.6%) female. Mean ages ranged from
21 to 97 years (mean 67, median 68). Precipitants of
CAT included chemotherapy (n=384; 84%), surgery
(n=14; 3%), radiotherapy (n=3; 0.7%) and acute
medical illness (n=3; 0.7%). Patient demographics are
summarised in table 1.
Of 25 eligible patients invited to participate, 20 con-
sented (male=10, female=10). Patients were aged
Table 1 Breadth of cancers reviewed with VTE
Cancer site Total N=457 (%)
DVT/PE
(N=205/252)
Lung
NSCLC 39 8/31
SCLC 6 2/4
Mesothelioma 5 1/4
Total 50 (11%) 11/39
Upper GI
Gastro-oesophageal 28 20/18
Hepatobiliary 12 10/2
Pancreatic 13 7/6
Total 53 (11.6%) 27/26
Breast 86 (18.8%) 51/35
Gynaecological
Ovary 27 9/18
Endometrium 13 3/10
Cervix 4 2/2
Vulva 5 2/3
Total 49 (10.7%) 16/33
Male urological
Renal 20 11(5 IVC)/10
Bladder 10 6/4
Prostate 36 20/16
Genital 5 3/2
Total 71 (15.5%) 39/32
Brain 8 (1.8%) 6/2
Colorectal
Caecum 14 6/8
Ascending/transverse/
descending colon
40 13/27
Sigmoid/rectum/anus 59 21/38
Total 113 (24.7%) 40/73
Unknown primary 9 (2%) 4/5
Miscellaneous 18 (3.9%) 10/8
DVT, deep vein thrombosis; PE, pulmonary embolus; NSCLC, non
small cell lung cancer, SCLC, small cell lung cancer; GI,
gastrointestinal; IVC, inferior vena cava; VTE, venous
thromboembolism.
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between 53 and 81 years old (mean 68) representing
seven different primary cancers , including lung (n=4),
colorectal (n=4), breast (n=4), prostate (n=2) and
ovarian (n=2). Participants had been receiving LMWH
for between 2 and 20 months. All 10 oncologists invited
to interview agreed to participate. Their specialist clin-
ical interests represented treatment of a breadth of
primary cancers.
We present the results of the audit and interviews
together. Data are presented within the context of the
quality measures identiﬁed from the initial audit (box 1).
These include quantitative data from the audit compo-
nent and qualitative data from patient and clinician
interviews.
Inconsistent management of CAT and adherence to
guidelines
The initial audit of practice identiﬁed that 33 different
oncologists and their respective junior medical staff were
responsible for the initial and ongoing management of
CAT. This resulted in marked variability of practice and
suboptimal adherence to clinical guidelines, particularly
with respect to correct choice of anticoagulant, duration
of treatment and dose prescribing. Following the intro-
duction of the CAT service, for consistency, two dedi-
cated CAT clinicians undertook the management of CAT
within the cancer centre.
The establishment of a clear CAT pathway and the
shared care agreement ensured that blood tests for
safety monitoring were appropriately requested and
reviewed. By reviewing patients at 1-month post-
diagnosis, all referred patients had their dalteparin dose
reduced as per protocol; a further safety net of checking
the shared care agreement had been completed and
sent to primary care. Furthermore, the pathway ensured
that a 6-month review became part of routine practice;
all patients were evaluated with respect to continuing
anticoagulation or stopping LMWH at this point,
dependent on disease status, ongoing treatments, bleed-
ing risk and patient preference.
Variable access to LMWH
Prior to this quality improvement initiative, over 90% of
patients with CAT relied on the regional cancer centre
to issue LMWH, with only 10% of eligible patients
able to access the anticoagulant from their community
family physician. Following the introduction of the
dedicated CAT service, prescribing within the commu-
nity of LMWH increased signiﬁcantly. Overall, 342
(75%) of 457 new cases of CAT were eligible under the
terms of the shared care agreement for LMWH prescrib-
ing by primary care. Of these, 334 (98%) cases were
managed under the shared care agreement, an overall
increase in community prescribing by 88%.
Need for information and support
Previous research has reported that patients felt that
being given the diagnosis of CAT was often a rushed
one, with insufﬁcient information or opportunity to ask
questions.19 In the current evaluation, patients felt that
the information leaﬂets provided information and
assurances:
The knowledge you get by reading the, all the different
literature makes it that much reassuring you know.
(Patient 06)
Patients reported being given a ‘thorough’ overview of
their condition with respect to their new diagnosis of
CAT.
Went right the way through of how the clots were ﬁrst
found, ﬁrst treated and like. (Patient 02)
Interviewees reported the depth of information given
was appropriate for their required level of understanding:
I think they told me what I could understand … I don’t
need… graphic details and chemical things. As long as
they tell me…they think that’s what caused it. That’s the
treatment we’re going to give you and it should sort it
out and this is what you need to look out for in the
future. (Patient 06)
Those requiring more information felt able to ask
questions, thereby addressing any other concerns.
Treats you as a person, not a number…any questions you
want to ask he’s, he’s willing to ask. You know he’s willing
to answer. Um, no he’s very very pleasant—it’s a lovely
clinic. (Patient 7)
Oncologists referring to the CAT clinic also reported
that the service offered patients the necessary informa-
tion and answers to questions as needed.
I think it’s a complex ﬁeld and I think we owe it to the
patients to get the best information for them and there
are lots of questions that are raised by patients in terms
of you know why they’ve developed a clot, what the
options are in terms of treatment and how long they
need to be on treatment that I don’t feel best qualiﬁed
to answer. (Oncologist 1)
Lack of consistent specialist expertise
Prior to the introduction of the CAT service, advice was
sought from six different haematology teams across four
different health boards. Through the introduction of
the CAT clinic, variation in practice was reduced by the
provision of local advice from one core team.
Oncologists considered that the CAT service offered con-
sistent access to clinical opinion on complex specialist
issues.
A very important resources in several respects, one is
having a single point of access for patients with cancer
associated thrombosis, they’re often very complex
patients with lots of different issues both you know
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physical and as you can imagine emotional, relating to
cancer. (Oncologist 11)
These clinics are a little bit of a godsend in terms of
being able to refer to someone for management of more
complex questions in the management of people who
are risk or who have had um cancer associated thrombo-
embolic events. (Oncologist 06)
Clinicians also reported that it was challenging to
keep up to date with the latest guidelines and data
within a rapidly changing clinical ﬁeld.
You know you’re getting the right up-to-date correct man-
agement without in the middle of a busy clinic where
you’re thinking of lots of other issues going on you know
am I doing this right? And where’s the guideline on this
and whatever. (Oncologist 08)
Additional benefits
Beyond demonstrating improvement in the four areas of
suboptimal practice that were initially identiﬁed, addi-
tional advantages to introducing the CAT clinic were
observed. The dedicated CAT clinics serve as an ideal
opportunity for oncology and haematology trainees to
learn about the complexities of holistic CAT manage-
ment within the context of the oncology journey. It has
also provided an ideal model for recruitment and
follow-up of clinical trials within the ﬁeld of CAT. The
service has also been identiﬁed as an excellent training
environment for trainee undergraduate and postgradu-
ate medics, clinical nurse specialists and prescribing
pharmacists.
DISCUSSION
The management for CAT is becoming an ever-complex
challenge, requiring consistent management, availability of
information and access to specialist evaluation, when
required. Suboptimal CAT management has a negative
impact on patient safety, quality of life and expenditure. A
dedicated CAT service goes some way to address such chal-
lenges with evidence of improvements in consistency of prac-
tice, access to specialist advice, access to anticoagulants and
patient experience. The service model presented is easily
replicable and provides a template for future cancer and
haematology services design. To date, two similar services
within the UK are being set up to manage regional CAT
issues. It is important to acknowledge that this service was
developed within the context of the National Health Service;
a centrally government-funded UK health system. As such,
the service may not be wholly transferrable across differing
healthcare systems around the globe. Nevertheless, we
believe that there are several transferrable principles, which
could reduce variation in clinical practice, waste and harm.
There are limitations to the service model, which we
plan to address over time. First, there is scope to
develop a more robust level of stafﬁng. At present, two
clinicians (SN and NP) provide the main clinical input,
which raises capacity issues especially during periods of
leave or staff sickness. Ideally, the service would best
serve patients at the point of VTE diagnosis, but current
resources cannot accommodate this. Second, it could
be argued that by establishing a dedicated clinic to
address VTE issues, it increases the number of clinic
appointments and thus burden for patients. Conversely,
some patients have preferred the additional input since
their fears around thrombosis recurrence were assuaged
by the specialist input. Third, the ﬁnancial implications of
the service have not been fully evaluated. While we have
seen a reduction in drug wastage and savings through
reducing the dose of LMWH appropriately, the service is
yet to undergo a formal health economic evaluation. This
would need to consider the additional costs generated
from providing staff and clinic space balanced against
savings associated avoidable admissions and episodes of
harm and the impact on patient quality-adjusted life years.
Finally, there is a risk that a specialist clinic could
de-skill generalist oncology healthcare professionals, par-
ticularly trainees. To counter this, we have ensured that
the clinic functions as a teaching clinic, which accommo-
dates staff each week to gain exposure to the ﬁeld.
There are several future challenges in optimising the
quality of care for CAT patients. One key issue, which
needs considering, lies with the ownership of the ‘CAT
problem’. Some consider it a haematological problem,
which should be managed by haematologists. However,
the majority of CAT cases are uncomplicated and the man-
agement is straightforward; as with non-cancer anticoagu-
lation that is managed in the main by non-haematology
services, so too could CAT, arguably, be taken over in the
primary care setting. Others may be of the view that it is
an oncological problem. However, we do not ask for all
patients with febrile neutropenia to be managed under
the infectious disease teams, so it seems counter-intuitive
that CAT, another common complication of chemother-
apy, should be managed by the haematologist. We have
concluded that a pragmatic approach is necessary; so long
as there remains a key clinical lead, who has access to
support from oncology and haematology when necessary,
the specialty with ultimate responsibility is irrelevant. The
most important requirement is for a multiprofessional
approach delivered by an interested and motivated team
that appreciates the physical and psychosocial complexities
of CATwithin the wider cancer context.
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